Emergent immunotherapy approaches for brain metastases

por Wang, Jianbo, Tawbi, Hussein A
Publicado 2021

The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition

por Kreidieh, Firas Y., Tawbi, Hussein A.
Publicado 2023

Clinical review: Serious adverse events associated with the use of rituximab - a critical care perspective

por Kasi, Pashtoon M, Tawbi, Hussein A, Oddis, Chester V, Kulkarni, Hrishikesh S
Publicado 2012

Treatment experience with encorafenib plus binimetinib for BRAF V600-mutant metastatic melanoma: management insights for clinical practice

por Augustyn, Kourtney, Joseph, Jocelyn, Patel, Anisha B., Razmandi, Azadeh, Ali, Amatul Noor, Tawbi, Hussein A.
Publicado 2023

High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute

por Davar, Diwakar, Ding, Fei, Saul, Melissa, Sander, Cindy, Tarhini, Ahmad A., Kirkwood, John M., Tawbi, Hussein A.
Publicado 2017

Society for Immunotherapy of Cancer (SITC) checkpoint inhibitor resistance definitions: efforts to harmonize terminology and accelerate immuno-oncology drug development

por Tawbi, Hussein A, Sullivan, Ryan J, Feltquate, David, LaVallee, Theresa, Rizvi, Naiyer A, Sharon, Elad, Sosman, Jeffrey, Kluger, Harriet M
Publicado 2023

Retinal imaging with en face and cross-sectional optical coherence tomography delineates outer retinal changes in cancer-associated retinopathy secondary to Merkel cell carcinoma

por Mesiwala, Nisreen K, Shemonski, Nathan, Sandrian, Michelle G, Shelton, Ryan, Ishikawa, Hiroshi, Tawbi, Hussein A, Schuman, Joel S, Boppart, Stephen A, Labriola, Leanne T
Publicado 2015

The great debate at “Melanoma Bridge 2018”, Naples, December 1st, 2018

por Ascierto, Paolo A., Bruzzi, Paolo, Eggermont, Alexander, Hamid, Omid, Tawbi, Hussein A., van Akkooi, Alexander, Testori, Alessandro, Caracò, Corrado, Puzanov, Igor, Perrone, Francesco
Publicado 2019

Bullous Pemphigoid-like Eruption Triggered by Targeted Therapy for Metastatic Melanoma

por ERIKSSON, Hanna, HANSSON, Johan, KRYNITZ, Britta, MASUCCI, Giuseppe, GIRNITA, Ada, LAPINS, Jan, HUEN, Auris O., TAWBI, Hussein A., DAVIES, Michael A., TETZLAFF, Michael T., CURRY, Jonathan L.
Publicado 2020

The interplay between neoantigens and immune cells in sarcomas treated with checkpoint inhibition

por Anzar, Irantzu, Malone, Brandon, Samarakoon, Pubudu, Vardaxis, Ioannis, Simovski, Boris, Fontenelle, Hugues, Meza-Zepeda, Leonardo A., Stratford, Richard, Keung, Emily Z., Burgess, Melissa, Tawbi, Hussein A., Myklebost, Ola, Clancy, Trevor
Publicado 2023

The efficacy of anti‐programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma

por Ogata, Dai, Haydu, Lauren E., Glitza, Isabella C., Patel, Sapna P., Tawbi, Hussein A., McQuade, Jennifer L., Diab, Adi, Ekmekcioglu, Suhendan, Wong, Michael K., Davies, Michael A., Amaria, Rodabe N.
Publicado 2021

MicroRNA expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy in metastatic melanoma treated on the ECOG-ACRIN trial E2603

por Villaruz, Liza C., Huang, Grace, Romkes, Marjorie, Kirkwood, John M., Buch, Shama C., Nukui, Tomoko, Flaherty, Keith T., Lee, Sandra J., Wilson, Melissa A., Nathanson, Katherine L., Benos, Panayiotis V., Tawbi, Hussein A.
Publicado 2015

Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma

por Butterfield, Lisa H., Vujanovic, Lazar, Santos, Patricia M., Maurer, Deena M., Gambotto, Andrea, Lohr, Joel, Li, Chunlei, Waldman, Jacob, Chandran, Uma, Lin, Yan, Lin, Huang, Tawbi, Hussein A., Tarhini, Ahmad A., Kirkwood, John M.
Publicado 2019

The “Great Debate” at Melanoma Bridge 2020: December, 5th, 2020

por Ascierto, Paolo A., Atkins, Michael B., Eggermont, Alexander M., Gershenwald, Jeffrey E., Grob, Jean-Jacques, Hamid, Omid, Sondak, Vernon K., Sosman, Jeffrey A., Tawbi, Hussein A., Weber, Jeffrey S., Caracò, Corrado, Osman, Iman, Puzanov, Igor
Publicado 2021

Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (C...

por Tawbi, Hussein A, Robert, Caroline, Brase, Jan C, Gusenleitner, Daniel, Gasal, Eduard, Garrett, James, Savchenko, Alexander, Görgün, Güllü, Flaherty, Keith T, Ribas, Antoni, Dummer, Reinhard, Schadendorf, Dirk, Long, Georgina V, Nathan, Paul D, Ascierto, Paolo A
Publicado 2022

The Great Debate at ‘Immunotherapy Bridge’, Naples, December 5, 2019

por Ascierto, Paolo A, Bifulco, Carlo, Galon, Jerome, Garbe, Claus, Khleif, Samir N, McQuade, Jennifer, Odunsi, Kunle, Okada, Hideho, Paulos, Chrystal M, Quezada, Sergio A, Tawbi, Hussein A, Timmerman, John, Trinchieri, Giorgio, Butterfield, Lisa H, Puzanov, Igor
Publicado 2020

The “Great Debate” at Melanoma Bridge 2021, December 2nd–4th, 2021

por Ascierto, Paolo A., Warner, Allison Betof, Blank, Christian, Caracò, Corrado, Demaria, Sandra, Gershenwald, Jeffrey E., Khushalani, Nikhil I., Long, Georgina V., Luke, Jason J., Mehnert, Janice M., Robert, Caroline, Rutkowski, Piotr, Tawbi, Hussein A., Osman, Iman, Puzanov, Igor
Publicado 2022

The “Great Debate” at Melanoma Bridge 2022, Naples, December 1st–3rd, 2022

por Ascierto, Paolo A., Blank, Christian, Eggermont, Alexander M., Garbe, Claus, Gershenwald, Jeffrey E., Hamid, Omid, Hauschild, Axel, Luke, Jason J., Mehnert, Janice M., Sosman, Jeffrey A., Tawbi, Hussein A., Mandalà, Mario, Testori, Alessandro, Caracò, Corrado, Osman, Iman, Puzanov, Igor
Publicado 2023

A mathematical model for the quantification of a patient’s sensitivity to checkpoint inhibitors and long-term tumour burden

por Butner, Joseph D, Wang, Zhihui, Elganainy, Dalia, Al Feghali, Karine A, Plodinec, Marija, Calin, George A, Dogra, Prashant, Nizzero, Sara, Ramírez, Javier Ruiz, Martin, Geoffrey V, Tawbi, Hussein A, Chung, Caroline, Koay, Eugene J, Welsh, James W, Hong, David S, Cristini, Vittorio
Publicado 2021

Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker

por Fischer, Grant M., Carapeto, Fernando C. L., Joon, Aron Y., Haydu, Lauren E., Chen, Huiqin, Wang, Fuchenchu, Van Arnam, John S., McQuade, Jennifer L., Wani, Khalida, Kirkwood, John M., Thompson, John F., Tetzlaff, Michael T., Lazar, Alexander J., Tawbi, Hussein A., Gershenwald, Jeffrey E., Scolyer, Richard A., Long, Georgina V., Davies, Michael A.
Publicado 2020